Age: 19.0
Sex: F
Vaccine: HPV4
Symptoms: Headache, Heart rate increased, Hyperhidrosis, Idiopathic intracranial hypertension, Impaired work ability
Clinical narrative: pots/dysautonomia; pseudotumor cerebri; autonomic, neurological, heterogenous autoimmune disease/vaccine-induced autoimmune disorder; generalized anxiety disorder; The patient did not receive the third vaccination until 25-JAN-2020; Information has been received from a lawyer referring to an adult female patient of unknown age regarding a case in litigation. Information about concurrent condition, history condition and concomitant medication was not reported. On 17-MAR-2010, at 19 years old, the patient received her first dosage of GARDASIL (strength, dose, route, lot#, and expiration date were not reported). Shortly after receiving the vaccine, her primary care physician diagnosed her as having generalized anxiety disorder. On 08-JUN-2010, the patient received her second dose of GARDASIL. After the second vaccination, she was diagnosed with syncope, dizziness, palpitations, orthostatic hypotension, postural orthostatic tachycardia syndrome (POTS), pseudotumor cerebri. Her symptoms were persistent, but stable following the second vaccination. The patient did not receive the third vaccination until 25-JAN-2020 (inappropriate schedule of product administration). After the third vaccination, the patient's symptoms significantly worsened and new symptoms appeared, including anxiety, blurry vision, chest tightness, diaphoresis, dizziness, headache, leg cramping, leg fatigue, lightheadedness, nausea, shortness of breath, and tingling. The medication she took to control her high heart rate became ineffective. By March 2020, her symptoms continued to worsen to the point where she sought care with a neurologist and a cardiologist. After consulting with these specialists, she was advised to have an updated tilt table test and electrocardiogram (EKG) to help determine the extent of her postural orthostatic tachycardia exacerbation. Her tilt table test was positive, with greater than 30 beat per minute increase on tilt. The patient agreed to her receiving the vaccine injections after having been exposed to marketing by company, that the vaccine was very safe, that the vaccine prevented cancer and that teenagers and young adults must get the vaccine. The patient relied upon the company's ubiquitous representations concerning the safety and efficacy of the vaccine, in consenting to her vaccination. Prior to receiving her injections, the patient no autoimmune diseases, and no autonomic issues. Soon after the April 2010 (also reported as 17-MAR-2010, conflicting information) and June 2010 vaccinations, the patient began experiencing symptoms caused by the vaccine and underwent various blood test spinal taps, injections, infusions, cardiac rehabilitation and hospitalizations from 2011 and beyond. The patient's vaccine injury of autonomic dysfunction, including POTS, was initially caused by the vaccinations received in April 2010 and June 2010. Her injury was significantly aggravated by her vaccination on 25-JAN-2020. The patient's health care provider recommended that she receive the vaccine, which was stated as a safe and effective vaccine for preventing cervical cancer. In light of the doctor's recommendations, as well as the company's relentless marketing and advertising messages, to which the patient had been exposed concerning the safety and efficacy of the vaccine, the patient consented to being injected with the vaccine. As a result of her post-vaccine symptoms, the patient was unable to engage in normal activities that a normal young person would enjoy. She had to temporarily withdraw from nursing school to attend to her debilitating injuries. After receiving the third vaccination and exacerbation of her injury, the patient's debilitating injuries again interfered with her work and daily activities. Based upon her chronic and severe post-vaccine symptoms, the patient had been diagnosed with various medical conditions, including but not limited to, POTS. The patient contended that her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) injections caused her to develop and aggravated her serious and debilitating injuries, including but not limited to autonomic, neurological, heterogenous autoimmune disease, POTS, and dysautonomia, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which are alleged herein and all of which were caused and aggravated by the vaccine or otherwise linked to her vaccine-induced autoimmune disorder. As a proximate result of the company's wrongful acts and omissions and its negligent and fraudulent testing, labeling, manufacturing, marketing and promotion of the vaccine, the patient had suffered and continued to suffer severe and permanent physical injuries, and associated symptomology and had suffered severe and permanent emotional injuries, including pain and suffering. The patient also had a substantial fear of suffering additional and ongoing harms, including but not limited to now being at an increased risk of cancer, and future symptoms and harms associated with her autoimmune disease and other injuries caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL). As a direct and proximate result of her vaccine-induced injuries, the patient had suffered and continued to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity, and she would continue to incur these losses and expenses in the future. The outcome of the events was not recovered. The causality between the events and Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) was considered to be related.  The lawyer considered the events to be disability.  Upon internal review, autoimmune disorder and pseudo-tumor cerebri were determined to be medically significant.